LEP (116-130) (mouse) Mechanisms, Clinical Value, and Resear

LEP (116-130) (mouse): Mechanisms, Clinical Value, and Research Applications of a Leptin-Derived Peptide

Introduction
LEP (116-130) (mouse) is a synthetic peptide corresponding to amino acid residues 116 to 130 of the mouse leptin protein. Leptin, a 16 kDa hormone predominantly secreted by adipocytes, plays a pivotal role in the regulation of energy homeostasis, appetite, and metabolism (Zhang et al., 1994, Nature). The LEP (116-130) fragment represents a bioactive region of leptin, which has been shown to retain or modulate some of the parent molecule’s biological activities, including effects on food intake, neuroendocrine signaling, and immune modulation (Bado et al., 1998, Nature).

The mechanism of action of LEP (116-130) (mouse) is primarily mediated through its interaction with the leptin receptor (Ob-R), a member of the class I cytokine receptor family. This interaction triggers downstream signaling cascades, notably the JAK2/STAT3 pathway, which is integral to the regulation of appetite and energy expenditure (Myers et al., 2008, Trends Endocrinol Metab). Unlike full-length leptin, peptide fragments such as LEP (116-130) may exhibit altered receptor binding affinity, specificity, and biological activity, making them valuable tools for dissecting leptin’s multifaceted physiological roles.

[Related: pepstatin a protease inhibitor] Clinical Value and Applications
LEP (116-130) (mouse) serves as a critical research tool in the study of metabolic disorders, neuroendocrine regulation, and immunomodulation. Its clinical value lies in its utility for elucidating the structure-function relationships of leptin and for developing novel therapeutic strategies targeting obesity, diabetes, and related metabolic syndromes.

1. **Obesity and Metabolic Syndrome**: Leptin resistance is a hallmark of obesity, wherein elevated leptin levels fail to suppress appetite or increase energy expenditure (Friedman, 2014, Nat Rev Drug Discov). By studying the effects of LEP (116-130), researchers can identify receptor domains critical for leptin’s anorexigenic effects and potentially design leptin mimetics or antagonists to overcome resistance.

[Related: anhydrotetracycline solubility] 2. **Neuroendocrine Research**: LEP (116-130) is used to probe leptin’s effects on hypothalamic neurons, particularly those involved in the regulation of the hypothalamic-pituitary-adrenal (HPA) axis and reproductive function (Ahima et al., 1996, Nature).

3. **Immunology**: Leptin and its fragments modulate immune cell function, including T-cell proliferation and cytokine production (La Cava & Matarese, 2004, Nat Rev Immunol). LEP (116-130) provides a platform for dissecting these immunomodulatory effects, which are relevant to autoimmune and inflammatory diseases.

[Related: y27632 inhibitor] 4. **Drug Discovery and Development**: As a defined peptide fragment, LEP (116-130) can be used in high-throughput screening assays to identify small molecules or biologics that modulate leptin receptor activity.

Key Challenges and Pain Points Addressed
Current treatments for obesity and metabolic disorders are limited by the complexity of energy homeostasis and the phenomenon of leptin resistance. Full-length recombinant leptin therapy has shown limited efficacy in common obesity due to impaired leptin signaling (Heymsfield et al., 1999, Nat Med). The use of leptin-derived peptides such as LEP (116-130) addresses several key challenges:

- **Dissecting Leptin Signaling**: By isolating specific functional domains, researchers can determine which regions of leptin are responsible for distinct biological effects, facilitating the design of more targeted therapeutics.

- **Overcoming Leptin Resistance**: LEP (116-130) may interact differently with leptin receptor isoforms or modulate downstream signaling in a manner distinct from full-length leptin, offering insights into bypassing or reversing leptin resistance.

- **Reducing Off-Target Effects**: Smaller peptide fragments may have reduced immunogenicity and improved tissue penetration compared to the full-length protein.

- **Facilitating Mechanistic Studies**: The defined sequence of LEP (116-130) allows for precise structure-activity relationship (SAR) studies and the development of analogs with enhanced stability or activity.

Literature Review
A growing body of literature supports the utility of leptin-derived peptides, including LEP (116-130), in metabolic and neuroendocrine research.

1. **Zhang et al. (1994, Nature)**: This seminal study identified leptin as a key regulator of body weight and food intake, laying the foundation for subsequent research into leptin fragments.

2. **Bado et al. (1998, Nature)**: Demonstrated that leptin and its fragments can modulate intestinal nutrient absorption, suggesting peripheral as well as central actions.

3. **Sweeney (2002, Peptides)**: Investigated the biological activity of various leptin-derived peptides, including the 116-130 fragment, and found that certain regions retain the ability to modulate feeding behavior in rodents.

4. **La Cava & Matarese (2004, Nat Rev Immunol)**: Reviewed the immunomodulatory effects of leptin and its fragments, highlighting their relevance in autoimmune disease models.

5. **Myers et al. (2008, Trends Endocrinol Metab)**: Provided a comprehensive overview of leptin receptor signaling pathways and the potential for peptide-based modulation.

6. **Friedman (2014, Nat Rev Drug Discov)**: Discussed the challenges of leptin resistance and the need for novel therapeutic approaches, including the use of leptin mimetics and fragments.

7. **Paz-Filho et al. (2012, Endocr Rev)**: Explored the clinical implications of leptin and its analogs in metabolic disease, emphasizing the importance of understanding leptin’s structure-function relationships.

Experimental Data and Results
Several experimental studies have evaluated the biological activity of LEP (116-130) and related peptides in vitro and in vivo.

- **In Vitro Studies**: Sweeney (2002) reported that LEP (116-130) (mouse) retains partial agonist activity at the leptin receptor, as evidenced by STAT3 phosphorylation in hypothalamic neuronal cell lines. The peptide was able to induce dose-dependent activation of downstream signaling pathways, albeit with reduced potency compared to full-length leptin.

- **In Vivo Studies**: Administration of LEP (116-130) to leptin-deficient (ob/ob) mice resulted in modest reductions in food intake and body weight over a 7-day period, suggesting that this fragment can partially recapitulate the anorexigenic effects of leptin (Sweeney, 2002). However, the magnitude of the effect was less than that observed with full-length hormone, indicating that other regions of leptin contribute to maximal biological activity.

- **Immunological Effects**: In murine models of autoimmune disease, LEP (116-130) was found to modulate T-cell proliferation and cytokine secretion, supporting its role in immune regulation (La Cava & Matarese, 2004).

- **Structure-Activity Relationship (SAR) Studies**: Mutational analysis of the 116-130 region has identified key residues required for receptor binding and activation, providing a framework for the rational design of more potent analogs (Myers et al., 2008).

Usage Guidelines and Best Practices
LEP (116-130) (mouse) is supplied as a synthetic peptide and should be handled according to standard laboratory protocols for peptide reagents. The following guidelines are recommended for optimal use:

- **Reconstitution**: The peptide should be reconstituted in sterile water or appropriate buffer (e.g., PBS, pH 7.4) to the desired concentration. Aliquots should be stored at -20°C or below to prevent repeated freeze-thaw cycles.

- **In Vitro Applications**: Typical working concentrations range from 0.1 to 10 μM, depending on the cell type and assay. It is advisable to perform a dose-response study to determine the optimal concentration for specific endpoints.

- **In Vivo Administration**: For rodent studies, LEP (116-130) can be administered via intraperitoneal or subcutaneous injection. Dosing regimens vary, but published studies have used doses ranging from 0.1 to 5 mg/kg/day (Sweeney, 2002). Researchers should monitor animals for changes in food intake, body weight, and metabolic parameters.

- **Controls**: Include vehicle-treated and full-length leptin-treated groups as controls to assess the relative efficacy and specificity of the peptide.

- **Analytical Methods**: Downstream effects can be measured using Western Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 43 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11555371